Ceterix Orthopaedics was issued U.S. Patent No. 10,004,492 for a method of placing a suture around a tear to repair damaged meniscus.
This is the second set of method claims describing the company’s proprietary Circumferential Compression Stitch. In 1Q18, the company was issued U.S. Patent No. 9,861,354 protecting products and methods—specifically, placing a circumferential compression stitch—to arthroscopically pass suture through soft tissue in very tight joint compartments.
The circumferential compression stitch is reportedly the only meniscus repair technique that treats the femoral and tibial sides of a tear simultaneously, enabling the repair of injuries that may previously have required partial or complete meniscus removal.
In 2Q18, the company received FDA 510(k) clearance to market the next-gen NovoStitch® Pro Meniscal Repair system to treat complex meniscal tears in knees, hips and shoulders. Enhancements in this latest version include an ergonomic and handle, visual cues for stitch placement and improvements to control and stability from upper jaw texturing.
Source: Ceterix Orthopaedics
Ceterix Orthopaedics was issued U.S. Patent No. 10,004,492 for a method of placing a suture around a tear to repair damaged meniscus.
This is the second set of method claims describing the company's proprietary Circumferential Compression Stitch. In 1Q18, the company was issued U.S. Patent No. 9,861,354 protecting products and...
Ceterix Orthopaedics was issued U.S. Patent No. 10,004,492 for a method of placing a suture around a tear to repair damaged meniscus.
This is the second set of method claims describing the company’s proprietary Circumferential Compression Stitch. In 1Q18, the company was issued U.S. Patent No. 9,861,354 protecting products and methods—specifically, placing a circumferential compression stitch—to arthroscopically pass suture through soft tissue in very tight joint compartments.
The circumferential compression stitch is reportedly the only meniscus repair technique that treats the femoral and tibial sides of a tear simultaneously, enabling the repair of injuries that may previously have required partial or complete meniscus removal.
In 2Q18, the company received FDA 510(k) clearance to market the next-gen NovoStitch® Pro Meniscal Repair system to treat complex meniscal tears in knees, hips and shoulders. Enhancements in this latest version include an ergonomic and handle, visual cues for stitch placement and improvements to control and stability from upper jaw texturing.
Source: Ceterix Orthopaedics
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
